Chinook Therapeutics, Inc. (KDNY)

Overview

Chinook Therapeutics, Inc. is a biotechnology company operating in the clinical development phase, focusing on the discovery, development, and market delivery of targeted medical therapies for kidney-related diseases. Located in Seattle, Washington, the company is committed to advancing its innovative treatments designed to address significant unmet medical needs in nephrology. The primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently undergoing Phase III clinical trials, targeting IgA nephropathy and various other glomerular diseases characterized by proteinuria. Chinook also emphasizes research and development to expand its portfolio of therapeutic solutions for rare and severe chronic kidney conditions.

Products and Services

• Atrasentan

  Atrasentan is an endothelin receptor antagonist currently in Phase III trials, aimed at providing a targeted treatment for patients with IgA nephropathy as well as other glomerular diseases. The drug focuses on reducing proteinuria, a common symptom associated with these kidney conditions.

• BION-1301

  BION-1301 is an anti-APRIL monoclonal antibody under investigation in a Phase I/II study for the treatment of IgA nephropathy. This product represents Chinook's commitment to developing innovative therapies that harness the immune system to restore kidney health and improve patient outcomes.

• CHK-336

  CHK-336 is a novel oral small molecule designed to inhibit LDHA, specifically targeting patients afflicted with primary hyperoxaluria, a rare genetic disorder that can lead to severe kidney damage. This investigational candidate aims to re-establish metabolic balance and prevent kidney complications associated with this condition.

• Research Initiatives

  In addition to its lead therapeutic candidates, Chinook Therapeutics is actively pursuing research and development efforts aimed at discovering solutions for other rare and chronic kidney diseases. The company's dedication to innovation seeks to expand its pipeline and address a broader range of kidney-related health challenges through scientific exploration.